If I had $5,000 to deploy into ASX mid-cap shares right now, I'd want businesses that are already executing at scale, but still have meaningful runway ahead of them.
Mid-caps are often where I see the most exciting balance of growth and proven economics. They're big enough to have systems and cash flow, but small enough that store rollouts, new product launches, or geographic expansion can still move the needle.
Here's where I would put my money.
Image source: Getty Images
Lovisa Holdings Ltd (ASX: LOV)
Lovisa is one of the cleanest global retail growth stories on the ASX in my view.
The company delivered revenue growth of 23.3% in the first-half of FY26 to $500.7 million, with comparable store sales up 2.2%. That tells me growth isn't just coming from new stores, but from existing locations as well.
What really stands out to me is the gross margin. Underlying gross margin expanded again to 82.9%, up 50 basis points. For a retailer expanding this quickly, that level of margin strength is impressive.
Store rollout remains the engine. Lovisa opened 85 new stores in the half, taking the network to 1,095 stores globally. With operations now spanning more than 50 markets, I believe the global footprint still has room to expand materially.
For a $5,000 mid-cap allocation, I like that Lovisa combines strong cash generation, margin discipline, and a clear growth lever in store rollout.
Breville Group Ltd (ASX: BRG)
Breville is a different kind of mid-cap. It's a premium consumer brand with global scale and pricing power.
The company delivered 10.1% revenue growth in the first half of FY26 to $1.1 billion, despite operating in what management described as a challenging tariff environment. Coffee continued to deliver double-digit growth, and new product launches contributed materially to performance.
What I find encouraging is how Breville managed US tariff pressure. By December, 80% of US gross profit was manufactured outside China. That kind of operational agility gives me confidence in management.
It is also leaning into enterprise-wide AI initiatives and continuing to invest in new geographies and product development. To me, that signals a company thinking long term, not just protecting short-term earnings.
Breville isn't a hyper-growth stock, but I believe it's a global brand builder with expanding optionality.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix is the higher-risk, higher-reward pick in this group. Revenue jumped 56% to US$803.8 million in FY25, driven by continued growth in its Precision Medicine franchise. That's not incremental growth. That's meaningful scale being built quickly.
The company is also investing heavily in its pipeline, with US$157.1 million deployed into R&D during the year. It now has multiple late-stage therapeutic assets across prostate, kidney, and brain cancer programs.
Importantly, Telix is guiding to FY26 revenue of US$950 million to US$970 million. That forward guidance tells me management sees continued commercial momentum.
This is not a defensive stock. But for a mid-cap allocation, I like having exposure to a company building a global radiopharmaceutical platform with expanding commercial and pipeline depth.
Foolish takeaway
If I were splitting $5,000 across ASX mid-cap shares today, I'd want a mix of global retail execution, premium consumer branding, and high-growth healthcare innovation.
Lovisa offers disciplined global store expansion and exceptional margins. Breville combines brand power with operational agility. Telix brings commercial growth and pipeline upside.
